Chronic kidney disease (CKD) represents a substantial health burden for a sizeable proportion of the US population. Nearly 40 million adults are estimated to be affected. Despite advances in strategies for managing patients with CKD, many patients still have residual risk of kidney disease progression and elevated cardiovascular risk. Newer therapies for CKD and DKD, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs), have recently been incorporated into evidence-based guidelines, representing substantial shifts in the treatment paradigm.

At the end of the presentation, participants will be able to: 

1. Detect and recognize CKD in patients with reduced kidney function to improve opportunities for early intervention. 
2. Implement screening for albuminuria in patients with diabetes in clinical practice to identify CKD as early as possible. 
3. Initiate therapy with evidence-based therapies, including SGLT-2 inhibitors and nonsteroidal MRAs, for patients with DKD when indicated. 
4. Compare and contrast differences between steroidal MRAs and nonsteroidal MRAs, including physiologic effects, therapeutic indications, and clinical outcomes.

Nephrotic vs nephritic is every PA student’s nightmare. And most PA-Cs do not like it either! And yet, nephrotic syndrome is out there and very often missed in primary care. When it is easy to catch, it should be on every differential and is the number 3 cause of kidney failure after diabetes and HTN. Using a series of real-life cases makes the trip through GN a fun ...and funny trip. Join us as we travel through the wilds of nephrotic, nephritic and glomerulonephritis.  At the end of this session, learners will be able to: 

1. Identify and explain nephrotic vs nephritic.
2. Review and identify incidence of glomerulonephritis diseases including how to diagnose.
3. Using cases, identify and review each type of GN. 

Emerging data surrounding SGLT2 inhibitors and MRAs exists, but uptake remains low. This talk will discuss the current clinical evidence and supporting guidelines.  At the end of this session, attendees will be able to: 

1. Identify gaps in current treatment of cardiovascular disease.
2. Discuss the pharmacokinetics of SGLT2 inhibitors and MRAs.
3. Discuss latest guidelines and emerging data surrounding SGLT2 inhibitor and MRA utilization.
   1. Develop new clinical strategies to help their individual patients with cardiovascular disease and CKD associated with type 2 diabetes mellitus.